Blaze Bioscience Announces Poster Presentation at ASCO 2015 Annual Meeting
Tumor Paint BLZ-100 results from first-in-human study in patients with skin cancer

SEATTLE, WA, USA and MELBOURNE, VIC, AUSTRALIA – May 27, 2015 – Blaze Bioscience, the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, and its subsidiary, Blaze Bioscience Australia Pty Ltd, announced today that the company's Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2015 Annual Meeting, taking place in Chicago, IL on May 29-June 2, 2015.

The poster presentation, titled “Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer,” will highlight the company's first-in-human study.

Details of the poster presentation are as follows:

**Trials in Progress Presentation**
Date: Monday, June 1, 2015
Time: 1:15 PM – 4:45 PM CDT
Location: S Hall A
Poster Number: 324b
Abstract Number: TPS9084

**About Tumor Paint BLZ-100**

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, colorectal, and sarcomas. BLZ-100 is currently in Phase 1 proof-of-concept clinical studies to evaluate safety and imaging characteristics of BLZ-100 in solid tumor cancers.

**About Blaze Bioscience**

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics, and is working to develop Tumor Paint™ products and Optide-based guided cancer therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop guided cancer therapeutics as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptide conjugates for therapeutic and imaging applications. For additional information, please visit [www.blazebioscience.com](http://www.blazebioscience.com).

# # #
Contact

Media-
Lauren Nelson
Blaze Bioscience, Inc.
(206) 535-8144
lauren.nelson@blazebioscience.com

Investor Relations-
Susan Specht Oram
SOS Communications LLC
(360) 535-3035
spechtoram@gmail.com